Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 401

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 401
---
 consideration arising from theacquisition of Translate Bio       | D.18.         |                                — |       — |     568 |                                — |       — |     441 |                                — |       — |     380 |
| Contingent consideration arising from acquisitionof Amunix                        | D.18.         |                                — |       — |       — |                                — |       — |     137 |                                — |       — |     165 |
| Other contingent consideration arising frombusiness combinations and acquisitions | D.18.         |                                — |       — |       1 |                                — |       — |       4 |                                — |       — |       4 |
| Non-current derivatives                                                           | D.20.         |                                — |     121 |       — |                                — |     164 |       — |                                — |     232 |       — |
| Current derivatives                                                               | D.19.5        |                                — |     337 |       — |                                — |     127 |       — |                                — |      94 |       — |
| Total financial liabilities measured at fair value                                |               |                                — |     458 |     641 |                                — |     291 |     709 |                                — |     326 |     779 |

No transfers between the different levels of the fair value hierarchy occurred during 2024 .

D.13. Cash and cash equivalents

| (€ million)               |  2024 |  2023 |   2022 |
| Cash                      | 1,270 | 1,461 |  1,385 |
| Cash equivalents(a)       | 6,171 | 7,249 | 11,351 |
| Cash and cash equivalents | 7,441 | 8,710 | 12,736 |

(a) As of December 31, 2024 , cash equivalents mainly comprised the following: (i) € 4,161million invested in euro and US dollar denominated money-market

mutual funds ( December 31, 2023 : € 5,349million ; December 31, 2022 : € 9,537million ); (ii) € 1,293million of term deposits ( December 31,

2023 : € 1,191million ; December 31, 2022 : € 1,167million ) and (iii) zero commercial paper ( December 31, 2023